No Data
No Data
Chengdu Easton Biopharmaceuticals (688513.SH): Indomethacin film obtains pharmaceutical registration certificate.
Chengdu Easton Biopharmaceuticals (688513.SH) announced on July 5th that its wholly-owned subsidiary, Chengdu Shuode Pharmaceutical Co., Ltd., recently received a Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for its pharmaceutical product called Indobufen Tablets. The main ingredient of Indobufen Tablets is Indobufen, which is used to treat ischemic cardiovascular diseases, ischemic cerebrovascular diseases, venous thrombosis, and to prevent blood clotting during hemodialysis.
Chengdu Easton Biopharmaceuticals (688513.SH): Has repurchased 1.1109% of the company's shares.
On July 4th, Gelunhui reported that Chengdu Easton Biopharmaceuticals (688513.SH) has cumulatively repurchased 1,961,076 shares of the company through centralized bidding trading method, accounting for 1.1109% of the company's current total share capital. The highest purchase price was 56.05 yuan/share, the lowest purchase price was 30.96 yuan/share, and the total transaction amount was RMB 82,654,844.89 (excluding stamp duty, trading commission, and other transaction fees) as of July 4, 2024.
Chengdu Easton Biopharmaceuticals (688513.SH): Has repurchased 0.8284% of the shares.
Chengdu Easton Biopharmaceuticals (688513.SH) announced on July 2 that the company did not repurchase shares in June 2024. As of the end of June 2024, the company has cumulatively repurchased 1,091,092 shares of the company through centralized bidding trading, accounting for 0.6181% of the current total share capital of the company. The highest price purchased was 56.05 yuan/share and the lowest price was 43.5 yuan/share, with a total transaction amount of RMB 54,282,923.09 (excluding transaction fees such as stamp duty and commission). As of the date of this announcement, the company has cumulatively repurchased shares through centralized bidding trading.
Chengdu Easton Biopharmaceuticals (688513.SH) has newly recognized Li Zhushi as a core technical personnel.
Chengdu Easton Biopharmaceuticals (688513.SH) announced that HONG CHEN, the company's deputy general manager and core technical staff...
Is It Smart To Buy Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) Before It Goes Ex-Dividend?
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) is
We Think Chengdu Easton Biopharmaceuticals (SHSE:688513) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
No Data